- Home
- MSD vs ACHV Comparison
MSD vs ACHV Comparison
Compare MSD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSD
- ACHV
- Stock Information
- Founded
- MSD 1993
- ACHV N/A
- Country
- MSD United States
- ACHV United States
- Employees
- MSD N/A
- ACHV N/A
- Industry
- MSD Trusts Except Educational Religious and Charitable
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MSD Finance
- ACHV Health Care
- Exchange
- MSD Nasdaq
- ACHV Nasdaq
- Market Cap
- MSD 154.7M
- ACHV 167.6M
- IPO Year
- MSD N/A
- ACHV N/A
- Fundamental
- Price
- MSD $7.39
- ACHV $5.12
- Analyst Decision
- MSD
- ACHV Strong Buy
- Analyst Count
- MSD 0
- ACHV 1
- Target Price
- MSD N/A
- ACHV $12.00
- AVG Volume (30 Days)
- MSD 70.2K
- ACHV 2.4M
- Earning Date
- MSD 01-01-0001
- ACHV 11-06-2025
- Dividend Yield
- MSD 11.26%
- ACHV N/A
- EPS Growth
- MSD N/A
- ACHV N/A
- EPS
- MSD N/A
- ACHV N/A
- Revenue
- MSD N/A
- ACHV N/A
- Revenue This Year
- MSD N/A
- ACHV N/A
- Revenue Next Year
- MSD N/A
- ACHV N/A
- P/E Ratio
- MSD N/A
- ACHV N/A
- Revenue Growth
- MSD N/A
- ACHV N/A
- 52 Week Low
- MSD $6.11
- ACHV $1.84
- 52 Week High
- MSD $7.46
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- MSD 47.79
- ACHV 70.28
- Support Level
- MSD $7.22
- ACHV $4.65
- Resistance Level
- MSD $7.51
- ACHV $5.07
- Average True Range (ATR)
- MSD 0.08
- ACHV 0.41
- MACD
- MSD 0.01
- ACHV 0.08
- Stochastic Oscillator
- MSD 58.62
- ACHV 76.00
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.